GAS6/TAM Axis as Therapeutic Target in Liver Diseases
Seminars in Liver Disease · 01.02.2024 · 44 (01) · 099-114
DOI: 10.1055/a-2275-0408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Seminars in Liver Disease, erschienen am 01.02.2024. Verfasst von Anna Tutusaus und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Death and Proliferation, IIBB-CSIC, IDIBAPS, Barcelona, Catalunya, Spain. Hauptthemen laut MEDLINE: Axl Receptor Tyrosine Kinase. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, Agència de Gestió d'Ajuts Universitaris i de Recerca, European Regional Development Fund.
Abstract (Originalsprache)
TAM (TYRO3, AXL, and MERTK) protein tyrosine kinase membrane receptors and their vitamin K-dependent ligands GAS6 and protein S (PROS) are well-known players in tumor biology and autoimmune diseases. In contrast, TAM regulation of fibrogenesis and the inflammation mechanisms underlying metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and, ultimately, liver cancer has recently been revealed. GAS6 and PROS binding to phosphatidylserine exposed in outer membranes of apoptotic cells links TAMs, particularly MERTK, with hepatocellular damage. In addition, AXL and MERTK regulate the development of liver fibrosis and inflammation in chronic liver diseases. Acute hepatic injury is also mediated by the TAM system, as recent data regarding acetaminophen toxicity and acute-on-chronic liver failure have uncovered. Soluble TAM-related proteins, mainly released from activated macrophages and hepatic stellate cells after hepatic deterioration, are proposed as early serum markers for disease progression. In conclusion, the TAM system is becoming an interesting pharmacological target in liver pathology and a focus of future biomedical research in this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cell Death and Proliferation, IIBB-CSIC, IDIBAPS, Barcelona, Catalunya, Spain.
- Barcelona Clinic Liver Cancer (BCLC) Group, Barcelona, Spain.
- Centro de Investigación Biomédica en Red sobre Enfermedades Cardiovasculares (CIBERCV), Barcelona, Comunidad de Madrid, Spain.
Förderung
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- European Regional Development Fund
- Instituto de Salud Carlos III
- Fundació la Marató de TV3
- Ministerio de Ciencia e Innovación
Zitieren
APA
Tutusaus, A., Morales, A., García de Frutos, P., & Marí, M. (2024). GAS6/TAM Axis as Therapeutic Target in Liver Diseases. Seminars in Liver Disease, 44(01), 099-114. https://doi.org/10.1055/a-2275-0408
Vancouver
Tutusaus A, Morales A, García de Frutos P, Marí M. GAS6/TAM Axis as Therapeutic Target in Liver Diseases. Seminars in Liver Disease. 2024;44(01):099-114. doi:10.1055/a-2275-0408
BibTeX
@article{Tutusaus2024,
author = {Tutusaus, Anna and Morales, Albert and García de Frutos, Pablo and Marí, Montserrat},
title = {GAS6/TAM Axis as Therapeutic Target in Liver Diseases},
journal = {Seminars in Liver Disease},
year = {2024},
volume = {44},
number = {01},
pages = {099--114},
doi = {10.1055/a-2275-0408}
}
EUVIMED